Lyell Immunopharma
a late-stage clinical company advancing next-generation chimeric antigen receptor and TCR-T cell therapies, with a June 2026 safety update on LYL273 in relapsed solid tumours; its epigenetic reprogramming technology addresses T-cell exhaustion, the central obstacle in solid-tumour cell therapy.
- Country
- United States
- Ticker
- LYEL
TCR-T (LYL273)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| TCR therapy (T-cell receptor engineered T cells) | therapeutics-platforms | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.